Navigation Links
Another LNA-based RNA Inhibitor Enters Clinical Trials
Date:3/20/2009

effective Drug Discovery Engine," said Henrik 0rum, CSO at Santaris Pharma. "We are very pleased by the achievement of this milestone and look forward to seeing other new LNA-based compounds advance into clinical trials across a range of therapeutic areas in the near future."

At the Association for Cancer Research (AACR) meeting being held April 18-22, 2009 in Colorado, Enzon Pharmaceuticals will present data on EZN3042 as well as on new LNA targets. Abstracts related to those targets are now available on http://www.aacr.org.

"Novel releasable PEG-nanoparticles enhance delivery of RNA antagonist oligonucleotides in tumor cells and in mice"

"EZN-2208, a novel pegylated SN-38 drug conjugate, markedly inhibits tumor growth and metastatic spreading of human neuroblastoma"

"Androgen receptor (AR) down regulation by locked nucleic acid antisense oligonucleotides specifically inhibits the growth of AR-positive tumor cells"

"The antitumor activity of EZN-4150, a potent LNA-based PIK3CA antagonist"

"EZN-3042, a novel locked nucleic acid oligonucleotide against survivin, inhibits survivin expression and confers taxol sensitivity"

"EZN-3920, an LNA antisense oligonucleotide RNA antagonist, down modulates HER3 expression and PI3K/Akt signaling pathway and enhances antiproliferative effect of Gefitinib in tumor cells"

http://www.santaris.com

About Santaris Pharma

Santaris Pharma is a privately held biopharmaceutical company with exclusive rights to use the LNA Drug Platform to develop new classes of RNA medicines targeting mRNAs and miRNAs associated with disease. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. In addition, Santaris Pharma is leveraging it
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Viatronix V3D-Colon Utilized in Another Landmark Study
2. Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
3. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
4. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
5. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
6. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
7. SuperGens PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia
8. New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
9. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
10. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
11. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... 30, 2015  Cleveland Clinic President Wael Barsoum ... last month that industry is compelled to adopt declining ... the efficiencies—and develop the transformational innovations -- required to ... were preceded by Doug Kohrs , past President ... who stressed that industry must add "episode of care," ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... has announced plans to release a newly redesigned website at Healthpointe.net. The new ... enhanced user experience. , The redesign serves to provide smoother interactions between ...
(Date:7/31/2015)... ... July 31, 2015 , ... ZH Healthcare announces a ... , What is HITaaS? Health IT as a Service (HITaaS) is a Healthcare dedicated ... a service (SaaS). , HITaaS manages all aspects of infrastructure, security, ...
(Date:7/31/2015)... ... July 31, 2015 , ... EB ... and Hospital Medicine Practice, is pleased to announce that it has partnered with ... format available on iPhones, iPads, and Android smartphones and tablets. , “The ...
(Date:7/31/2015)... ... ... The Radiology Business Management Association’s 2015 Fall Educational Conference ... Care: A View From Capitol Hill” on Sunday, Sept. 27, 2015, in Austin, Tex. ... has a special understanding of the real world impact of health care policy issues,” ...
Breaking Medicine News(10 mins):Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Healthpointe Announces Newly Redesigned Website 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3
... new vaccine called the TAT vaccine has been developed in ... date. And more importantly it has had a 71% success ... for human testing and this may be the brightest hope ... of the Department of Virology at Italy’s National Health Institute ...
... social neglect and being unwanted even by near and dear ... like the other people - wherever they want and whenever ... passengers. Others are just indifferent. Leaving the ethical issues aside, ... of, many reasons. Primarily the physicians of these patients do ...
... The outgoing U.S. president Bill Clinton will be remembered as ... by becoming the first American president in history to be ... to win at the senate did he save himself and ... of many burning controversies throughout his term and his mid ...
... pregnancy can lead to increased risk of heart problems ... environment contribute to several aspects of cardiovascular risks in ... ,People whose mothers starved during the first 13 ... their adult life, Starvation during mid or late pregnancy ...
... cancer is pancreatic cancer, though it isn’t very common. Globally ... is some hope for the unfortunate victims. A new vaccine ... it has increased the survival rates in many. ,Vaccines ... In cancer, however, they are used along with other therapies ...
... new research into how our immunity works says stress reduces ... long we have agreed that stress is bad for our ... is sure to cause a lot of concern. , ... claming many victims every day, the new buzzword is immunity ...
Cached Medicine News:
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Zeiss surgical...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
Medicine Products: